ArticleCureus2025
Antimicrobial Resistance: An Emerging Global Threat to Modern Medicine.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline.Antibiotics (Basel, Switzerland) · 2026Review
- Molecular and environmental drivers of antimicrobial resistance: global epidemiology, resistome dynamics, and one health strategies.Archives of microbiology · 2026Review
- Advancements in Technologies Targeting Horizontal Gene TransferRoutes to Control Drug Resistance Evolution.ACS bio & med chem Au · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) constitutes a critical challenge in contemporary healthcare. The proliferation of resistant bacteria threatens the safety of surgical procedures, cancer chemotherapy, and critical care worldwide. Increased mortality from drug-resistant infections results from both microbial adaptation and systemic deficiencies in surveillance, stewardship, and innovation. Although global awareness has increased, the development of new antibiotics remains limited, and disparities in access to effective therapies continue. Addressing this crisis requires a unified One Health approach that integrates human, animal, and environmental health. This editorial analyzes the scope of AMR, the economic and regulatory factors driving the decline in antibiotic innovation, and the urgent reforms needed to sustain modern medical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.